Trials / Completed
CompletedNCT00358644
Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML)
A Phase II Study of Decitabine For the Front-line Treatment of Older Patients With Acute Myeloid Leukemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 55 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to estimate the rate of complete remission, as well as overall survival, in older patients with Acute Myeloid Leukemia (AML).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Decitabine | 20 mg/m\^2, IV on days 1-5 of each 28 day cycle; until death, progression or unacceptable toxicity develops. |
Timeline
- Start date
- 2005-03-01
- Primary completion
- 2008-02-01
- Completion
- 2008-12-01
- First posted
- 2006-08-01
- Last updated
- 2013-05-20
- Results posted
- 2009-09-07
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00358644. Inclusion in this directory is not an endorsement.